Nektar Therapeutics (NKTR) Stock Forecast & Price Target
Score
Nektar Therapeutics price target
| NKTR | |
|---|---|
| Low | $50.00 |
| Average | $107.20 |
| High | $153.00 |
| Upside vs current price | +187.6% |
The average target of $107.20 is +187.6% versus the current NKTR price of $37.27.
Nektar Therapeutics analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 10 |
| Hold | 4 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
15 analysts cover NKTR.
Nektar Therapeutics EPS and revenue estimates
The estimate table for the Nektar Therapeutics keeps 2026 EPS $-8.08, 2027 EPS $-10.50, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-8.08 | $41.82M |
| 2027 | $-10.50 | $53.42M |
Is Nektar Therapeutics a buy or sell?
Of the 15 analysts covering Nektar Therapeutics, 11 rate it a buy (1 strong buy and 10 buy), 4 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The NKTR consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.
The average target of $107.20 implies +187.6% versus the current price of $37.27.
the Nektar Therapeutics closes with 11 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Nektar Therapeutics forecast
Analysts are far apart on NKTR. The published low is $50.00, the average is $107.20, and the high is $153.00.
From today's $37.27 print, the NKTR average target is +187.6% away.
Most of the NKTR coverage agrees: 11 of 15 analysts are on the buy side, 4 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Earnings estimates for NKTR are falling: 2026 $-8.08, then 2027 $-10.50.
Coverage of NKTR is broad at 15 analysts, and the average is a crowd rather than a single desk.
Nektar Therapeutics forecast questions
What is the NKTR price target?
The published range for NKTR is $50.00 to $153.00, with an average of $107.20. That average is +187.6% versus the current price of $37.27.
Is Nektar Therapeutics a buy or sell?
Of the 15 analysts covering Nektar Therapeutics, 11 rate it a buy, 4 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for NKTR is 11 on the buy side, 4 at hold, and 0 on the sell side.
What is the EPS estimate for Nektar Therapeutics?
Analyst EPS estimates for Nektar Therapeutics: 2026 $-8.08, 2027 $-10.50.
What is the revenue estimate for Nektar Therapeutics?
Analyst revenue estimates for Nektar Therapeutics: 2026 $41.82M, 2027 $53.42M.
How many analysts cover NKTR?
15 analysts cover NKTR. Their consensus on NKTR is Buy, across those 15.